Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026
Novo Nordisk’s phase 3 CagriSema REDEFINE 9 trial showed estimated average weight loss of 20.7% and 21.0% at 68 weeks with lower CagriSema doses, versus 2.0% with placebo. Results were presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.
